Home > Cardiovascular Generic Drugs: Prospects and Opportunities to 2012 (Table of Contents)

Cardiovascular Generic Drugs: Prospects and Opportunities to 2012

Espicom Healthcare Intelligence
December 31, 2007
186 Pages - SKU: ESPI1657179

Abstract Table of Contents Search inside this report Related Reports

Foreword
Executive Summary
Cholesterol, Lipids and Triglycerides
The cholesterol management drugs market
Statins: NICE Guidance on the use of statins; Crestor (rosuvastatin); Patents; Generic Company Activity; Safety Issues; Market Outlook; Lescol (fluvastatin); Patents; Generic Company Activity; Orbus Pharma; Market Outlook; Lipitor (atorvastatin); Patents; Ranbaxy’s global battle against Lipitor patents; US; Canada; Austria; Denmark; Finland; Ireland; Norway; Spain; UK; Australia; Andean Pact countries; Other generic company activity; Morepen Laboratories; Market Outlook; Pravachol (pravastatin); Patents; Generics; Market Outlook; Zocor (simvastatin); Generics; Market Outlook; Mevacor (lovastatin); Generics; Altoprev (lovastatin XR)
Other Antihyperlipidaemic Agents: Zetia (ezetimibe); NICE Guidance on ezetimibe; Patents; Generic Company Activity; Market Outlook; TriCor (fenofibrate); Patents; Generics; Teva; Lipofen (fenofibrate); Patents; Market Outlook; Niaspan (niacin); Patents & Litigation; Market Outlook
Combination Products: Vytorin (ezetimibe+simvastatin); Patents; Market Outlook; Advicor (niacin+lovastatin); Patents & Litigation; Caduet (amlodipine+atorvastatin); Patents; Generic Company Activity; Market Outlook
The next five years: Generics; Potential new products; New combinations; ABT-335; AVE 5530; Anacetrapib; AEGR-733; Hypertension; The hypertension drugs market; ARBs; Aprovel (irbesartan); Patents; Generic Company Activity; Market Outlook; Diovan/Co-Diovan (valsartan); Patents; Generic Company Activity; Market Outlook; Cozaar/Hyzaar (losartan); Patents; Generic Company Activity; Market Outlook; Micardis (telmisartan); Patents; Generic Company Activity; Market Outlook; Atacand (candesartan cilexetil); Patents; Generic Company Activity; Market Outlook; Benicar (olmesartan); Patents; Generic Company Activity; Market Outlook
Dihydropyridine Calcium Channel Blockers: Norvasc (amlodipine); Patents; Generics; Mylan; Apotex; Synthon Pharmaceuticals; Market Outlook; Adalat (nifedipine); Patents; Generics; Market Outlook; Zanidip (lercanidipine); DynaCirc (isradipine); Patents; Generics
ACE Inhibitors: Vasotec (enalapril); Generics; Altace/Delix/Tritace (ramipril); Combinations; Patents; Generics; Europe; US; Cobalt Pharmaceuticals; Lupin; Market Outlook; Accupril (quinapril); Patents; Generics; Market Outlook
Beta Blockers: Coreg (carvedilol); Patents; Generics; Market Outlook; Seloken/Toprol-XL (metoprolol succinate); Patents; Generics; Orbus Pharma; Market Outlook; Concor (bisoprolol); Generics
Alpha Adreno-Receptor Antagonists: Cardura (doxazosin); Generics
Combination Products: Lotrel (amlodipine+benazepril); Patents; Generics; Market Outlook; Azor (amlodipine+olmesartan); Zanipress (lercanidipine+enalapril)
New Drug Class - Oral Renin Inhibitors: Rasilez/Tekturna (aliskiren)
The next five years: Generics; Novel drugs in development; Nebivolol; Cleviprex (clevidipine); Darusentan; Ilepatril; Company Profiles; Actavis; Cholesterol and hypertension products; Financials; Major Developments; Actavis acquires Abrika; Actavis strengthens its position in India; Actavis acquires Alpharma’s Human Generics business; Apotex; Cholesterol & hypertension products; Patent litigation; AstraZeneca files suit over Crestor; Teva sues Apotex over carvedilol; Apotex wins UK perindopril patent challenge; Norvasc patent litigation; Aurobindo Pharma; Cholesterol and hypertension products; Financials; Major Developments; AstraZeneca files action over Crestor; Pharmacin acquisition; Acquisition of US facility; Milpharm: Aurobindo’s first acquisition in Europe; Caraco Pharmaceutical Laboratories; Hypertension products; Financials
Dr. Reddy’s: Cholesterol and hypertension products; Cardiovascular R&D; Financials; Major Developments; Dr. Reddy’s and Torrent sign Russian lisinopril agreement; Betapharm Acquisition
Glenmark Pharmaceuticals: Cholesterol and hypertension products; Financials; Major Developments; Acquisition of majority shareholding in Medicamenta
Impax Laboratories: Cholesterol and hypertension products; Financials
InvaGen Pharmaceuticals: Products; Collaborative agreement with Glenmark Pharmaceuticals
Lupin: Cholesterol and hypertension products; Financials
Mylan: Cholesterol and hypertension products; Financials; Major Developments; Merck Generic Acquisition; Matrix Laboratories Acquisition; Crestor patent infringement litigation
Par Pharmaceutical: Cholesterol and hypertension products; Financials; Major Developments; IntelliPharmaCeutics announces equity investment by Par Pharmaceutical; Crestor patent infringement litigation; AstraZeneca/Par enter agreement for generic version of Toprol-XL; Reliant files patent infringement lawsuit against Par over Rythmol
Ranbaxy: Cholesterol and hypertension products; Financials; Major Developments; Ranbaxy acquires Be-Tabs for US$71 million; Ranbaxy acquires GSK's Mundogen generic business in Spain; Ranbaxy acquires Terapia; Ranbaxy’s global battle against Lipitor patents; Roxane Laboratories; Cholesterol and hypertension products; Financials; Sandoz; Cholesterol & hypertension products; Financials; Major Developments; Sandoz completes purchase of Hexal and Eon Labs; Crestor patent infringement litigation; Teva Pharmaceutical Industries; Cholesterol & hypertension products; Financials; Watson Pharmaceuticals; Cholesterol & hypertension products; Financials; Major Developments; Sandoz' ANDA for generic Toprol-XL approved further to agreement with Watson; Watson completes acquisition of Andrx; Zydus Cadila; Cholesterol & hypertension products; Financials; SOURCES; Espicom Sources; Others
List of Tables: US Patent Expiry for Cholesterol Management Drugs; Sales of Branded Cholesterol Management Drugs, 2005-2006 (US$ Million); FDA ANDA Approvals of Cholesterol Management Drugs, 2001-2007; Crestor Sales, 2003-2006 (US$ Million); Crestor US Patents; Lescol Sales, 2002-2006 (US$ Million); Lescol US Patents; Lipitor Sales, 2002-2006 (US$ Million); Lipitor US Patents; Pravachol Sales, 2002-2006 (US$ Million); Mevalotin Sales, 2003-2007 (¥ Million & US$ Million); Pravachol US Patents; FDA ANDA Approvals for Pravastatin; Zocor Sales, 2002-2006 (US$ Million); FDA ANDA Approvals for Simvastatin; FDA ANDA Approvals for Lovastatin; Zetia Sales, 2003-2006 (US$ Million); Zetia US Patents; TriCor Sales, 2002-2006 (US$ Million); TriCor US Patents; FDA ANDA Approvals for Fenofibrate; Tentative ANDA Approvals for Fenofibrate; Lipofen US Patent; Niaspan Sales, 2002-2006 (US$ Million); Niaspan US Patents; Vytorin Sales, 2004-2006 (US$ Million); Vytorin US Patents; Advicor Sales, 2002-2006 (US$ Million); Advicor US Patents; Caduet Sales, 2004-2006 (US$ Million); Caduet US Patents; Paragraph IV Patent Certification for Amlodipine+Atorvastatin; US Patent Expiry for Hypertension Drugs; Sales of Branded Hypertension Drugs, 2005-2006 (US$ Million); FDA ANDA Approvals of Hypertension Drugs, 2005-2007; Aprovel/Avapro/Karvea Sales, 2002-2006 (Euros & US$ Million); FDA Tentative ANDA Approvals for Irbesartan; Diovan/Co-Diovan Sales, 2002-2006 (US$ Million); Diovan US Patents; Cozaar/Hyzaar Sales, 2002-2006 (US$ Million); Cozaar/Hyzaar US Patents; FDA Tentative ANDA Approvals for Losartan; Micardis Sales, 2002-2006 (Euros & US$ Million); Micardis Sales in Japan, 2003-2007 (¥ & US$ Million); Micardis US Patents; Atacand Sales, 2002-2006 (US$ Million); Blopress Sales, 2003-2007 (¥ Billion & US$ Million); Atacand/Atacand Plus US Patents; Benicar/Olmetec Sales, 2004-2007 (¥ Billion & US$ Million); Benicar US Patents; Norvasc Sales, 2002-2006 (US$ Million); Amlodin Sales, 2003-2007 (¥ Billion & US$ Million); UK Marketing Authorisations for Generic Amlodipine Besylate, 2006-07; FDA ANDA Approvals for Amlodipine Besylate; Adalat Sales, 2002-2006 (Euros & US$ Million); Adalat US Patents; FDA ANDA Approvals for Nifedipine, 2002-2007; Zanidip Sales, 2002-2006 (Euros & US$ Million); DynaCirc CR US Patents; FDA ANDA Approvals for Isradipine; Vasotec/Vaseretic Sales, 2002-2006 (US$ Million); FDA ANDA Approvals for Enalapril; Altace/Delix/Tritace Sales, 2001-2006 (Euros & US$ Million); Altace US Patents; FDA Tentative ANDA Approvals for Ramipril; Accupril/Accuretic Sales, 2002-2006 (US$ Million); Accupril US Patents; US FDA ANDA Approvals for Quinapril; Coreg/Dilatrend Sales, 2002-2006 (£ & US$ Million); Coreg US Patents; FDA ANDA Approvals for Carvedilol; Seloken ZOK/Toprol-XL Sales, 2002-2006 (US$ Million); Toprol-XL US Patents; FDA ANDA Approval for Metoprolol Succinate; Concor Sales, 2002-2006 (EUR & US$ Million); FDA ANDA Approvals for Bisoprolol; Cardura Sales, 2002-2006 (US$ Million); FDA ANDA Approvals for Doxazosin; Lotrel Sales, 2002-2006 (US$ Million); Lotrel US Patents; FDA ANDA Approval for Amlodipine+Benazepril; FDA Tentative ANDA Approval for Amlodipine+Benazepril; Leading Hypertension/Hypercholesterolaemia Products, 2006; Actavis: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2000-2007; Actavis Financial Results, 2003-2006 (EUR & US$ Million); Apotex: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2002-2007; Aurobindo: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2006-2007; Aurobindo Pharma: Financial Results, 2003-2007; Caraco: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2003-2007; Caraco Financial Results, 2003-2007 (US$ Million); Dr. Reddy’s Leading Cardiovascular Brands in India, 2005-2007; Dr Reddy's: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2001-2007; Dr Reddy's: Tentative ANDA Approvals for Cholesterol & Hypertension Drugs; Dr. Reddy’s: Financial Summary, 2003-2007; Glenmark FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2007; Glenmark: Financial Results, 2003-2007; Impax: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2003-2007; Impax: Tentative ANDA Approvals for Cholesterol & Hypertension Drugs; Impax Laboratories Financial Results, 2003 (US$ Million); InvaGen: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2005-2007; Lupin: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2002-2007; Lupin: Financial Results, 2003-2007; Mylan: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2000-2007; Genpharm FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2000-2007; Mylan: Tentative ANDA Approvals for Cholesterol & Hypertension Drugs; Generics (UK) Ltd: UK Marketing Authorisation for Cholesterol & Hypertension Drugs, 2004-2007; Mylan Financial Results, 2003-2007 (US$ Million); Par Sales of Selected Cardiovascular Generics, 2004-06 (US$000s); Par Pharmaceutical: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2002-2007; Kali Laboratories: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2007; Par Pharmaceutical: Tentative ANDA Approvals for Cholesterol & Hypertension Drugs; Par Pharmaceutical Financial Results 2003-06 (US$ Million); Ranbaxy: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2000-2007; Ranbaxy Financial Results, 2003-2006; Roxane: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2007; Roxane: Tentative ANDA Approvals for Cholesterol & Hypertension Drugs; Roxane Net Sales, 2005-2006 (EUR & US$ Million); Sandoz: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2000-2007; Lek: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2000-2007; Sandoz: UK Marketing Authorisation for Cholesterol & Hypertension Drugs, 2004-2006; Sandoz Financial Results, 2004-2006 (US$ millions); Teva: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2000-2007; IVAX: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2000-2006; Teva: Tentative ANDA Approvals for Cholesterol & Hypertension Drugs; Teva Financial Results, 2002-2006 (US$ millions); Watson: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2000-2007; Watson Financial Results, 2002-2006 (US$ Million); Zydus: FDA ANDA Approvals for Cholesterol & Hypertension Drugs, 2005-2007; Zydus: Tentative ANDA Approvals for Cholesterol & Hypertension Drugs; Zydus Cadila: Consolidated Results, 2006-2007; Cadila Healthcare: Financial Results, 2003-2007
List of Figures: Crestor Sales, 2003 - 2012 (US$ Million); Lescol Sales 2003-2012 (US$ Million); Lipitor Sales 2003-2012 (US$ Million); Pravachol Sales 2003-2012 (US$ Million); Mevalotin Sales 2003-2012 (US$ Million); Zocor Sales 2003-2012 (US$ Million); Zetia Sales 2003-2012 (US$ Million); TriCor Sales, 2003-2012 (US$ Million); Vytorin Sales, 2004-2012 (US$ Million); Caduet Sales 2004-2012 (US$ Million); Aprovel/Avapro Sales 2003-2012 (US$ Million); Diovan/Co-Diovan Sales 2003-2012 (US$ Million); Cozaar/Hyzaar Sales 2003-2012 (US$ Million); Micardis Sales 2003-2012 (US$ Million); Atacand Sales 2003-2012 (US$ Million); Benicar/Olmetec Sales 2003-2012 (US$ Million); Norvasc Sales 2003-2012 (US$ Million); Adalat Sales, 2003-2012 (US$ Million); Altace/Delix/Tritace Sales 2003-2012 (US$ Million); Accupril Sales 2003-2012 (US$ Million); Coreg Sales, 2003-2012 (US$ Million); Seloken/Toprol-XL Sales 2003-2012 (US$ Million); Lotrel Sales, 2003-2012 (US$ Million)

Research assistance

We can help you find what you need. Call us or write us:

US: 800.298.5699

Int'l: +1.240.747.3093

Need help in your search?

Related Markets

Cardiovascular Reports

Share this report

Email a colleague

Other tasks

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!